Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-MI: IV Iron vs Oral Iron in Myocardial Infarction
NCT05309499Completed
- Sponsor
- Kazan State Medical University
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ferric carboxymaltose in myocardial infarction (MI) and iron deficiency anemia (IDA) (3 arms), sponsored by Kazan State Medical University. Primary endpoint: Decrease in the Wall Motion Score Index at 1 year. Started Dec 2021; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
myocardial infarction (MI)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05309499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309499.